Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Agressive or transformed MCL: prognostic factors, outcomes & mutational profile

Preetesh Jain • 2 Jul 2019
ICML 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma

Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, presents the comprehensive analysis of prognostic factors, outcomes and mutation profiles in patients with mantle cell lymphoma (MCL) with an aggressive histology (blastoid/pleomorphic) or transformed MCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Preetesh Jain

Trials of interest in the mantle cell lymphoma space at ASH 2023 5:06
Trials of interest in the mantle cell lymphoma space at ASH 2023
Preetesh Jain • 8 Dec 2023
Future work in mantle cell lymphoma 0:58
Future work in mantle cell lymphoma
Preetesh Jain • 15 Jun 2023
Selecting BTK inhibitors for patients with MCL 1:32
Selecting BTK inhibitors for patients with MCL
Preetesh Jain • 15 Jun 2023
The unmet needs of patients with MCL who relapse after CAR-T 1:18
The unmet needs of patients with MCL who relapse after CAR-T
Preetesh Jain • 15 Jun 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals